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Abstract— Alzheimer’s disease (AD) is one of the most 
prominent neurodegenerative disorders. The aim of this 
research work is to study the magnetoencephalogram (MEG) 
background activity in AD patients using two scaling analysis 
methods: detrended fluctuation analysis (DFA) and backward 
detrended moving average (BDMA). Both measures have been 
designed to quantify correlations in noisy and non-stationary 
signals. Five minutes of recording were acquired with a 148-
channel whole-head magnetometer in 15 patients with probable 
AD and 15 control subjects. Both DFA and BDMA exhibited 
two scaling regions with different slopes. Significant differences 
between both groups were found in the second region of DFA 
and in the first region of BDMA (p < 0.01, Student’s t-test). 
Using receiver operating characteristic curves, accuracies of 
83.33% with DFA and of 80% with BDMA were reached. Our 
findings show the usefulness of these scaling analysis methods to 
increase our insight into AD. 
I. INTRODUCTION 
AGNETOENCEPHALOGRAPHY (MEG) is a non-invasive 
technique that allows recording the magnetic fields  
produced by brain activity. It provides an excellent temporal 
resolution, orders of magnitude better than other methods for 
measuring cerebral activity, as magnetic resonance imaging, 
single-photon-emission computed tomography or positron-
emission tomography [1]. A good spatial resolution can also 
be achieved due to the large number of sensors. Moreover, 
the activity in different parts of the brain can be monitored 
simultaneously with whole-head equipments, such as the 
magnetometer used in the present study [1]. On the other 
hand, the magnetic signals generated by the human brain are 
extremely weak. Thus, SQUID (Superconducting QUantum 
Interference Device) sensors are necessary to detect them. In 
addition, MEG signals must be recorded in a magnetically 
shielded room. Thus, MEG is characterized by limited 
availability and high equipment cost. 
 Alzheimer’s disease (AD) is a progressive and irreversible 
brain disorder of unknown aetiology. It is the main cause of 
dementia in western countries, accounting for 50-60% of all 
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cases [2]. AD affects 1% of population aged 60-64 years, but 
the prevalence increases exponentially with age, so around 
30% of people over 85 years suffer from this disease [3]. 
Additionally, due to the fact that life expectancy has 
significantly improved in western countries in the last 
decades, it is expected that the number of people with 
dementia increase up to 81 million in 2040 [3]. AD is 
characterized by neuronal loss and the appearance of neuritic 
plaques containing amyloid-β-peptide and neurofibrillary 
tangles [4]. Clinically, this disease manifests as a slowly 
progressive impairment of mental functions whose course 
lasts several years prior to death [4]. Usually, AD starts by 
destroying neurons in parts of the patient’s brain that are 
responsible for storing and retrieving information. Then, it 
affects the brain areas involved in language and reasoning. 
Eventually, many other brain regions are atrophied. Thus, 
AD patients may wander, be unable to engage in 
conversation, appear non-responsive, become helpless and 
need complete care and attention [5]. Although a definite AD 
diagnosis is only possible by necropsy, a differential 
diagnosis with other types of dementia and with major 
depression should be attempted. The differential diagnosis 
includes medical history studies, physical and neurological 
evaluation, mental status tests, and neuroimaging techniques. 
The electromagnetic brain activity has been researched in 
the last decades by means of non-linear techniques. 
Correlation dimension has been widely used to study the 
brain activity in AD patients [6, 7]. Nevertheless, reliable 
estimation of this classical measure requires a large number 
of data points and stationary and noise-free time series [8]. 
As these problems cannot be solved for physiological 
signals, other non-linear methods are necessary to study 
brain recordings. In fact, Lempel-Ziv complexity [9-11], 
Higuchi’s fractal dimension [12], approximate entropy [11], 
sample entropy [10], synchronization likelihood [13], phase 
lag index [14], and auto-mutual information [15] have been 
already used to analyze the MEG activity in AD.   
In this preliminary study, we have examined the MEG 
background activity in patients with probable AD and in age-
matched control subjects using two scaling analysis 
measures: detrended fluctuation analysis (DFA) and 
backward detrended moving average (BDMA). Our purpose 
is to test the hypothesis that the neuronal dysfunction in AD 
is associated with differences in the dynamical processes 
underlying the MEG recording. 
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II. MATERIAL AND METHODS 
A. Subjects and MEG recording 
The signals were recorded using a 148-channel whole-
head magnetometer (MAGNES 2500 WH) located in a 
magnetically shielded room. The subjects lay comfortably on 
a patient bed, in a relaxed state and with their eyes closed. 
They were asked to stay awake and to avoid eye and head 
movements. For each subject, five minutes of recording were 
acquired at a sampling frequency of 678.17 Hz. These 
recordings were down-sampled by a factor of four, obtaining 
a sampling rate of 169.55 Hz. Data were digitally filtered 
between 0.5 and 40 Hz. Finally, artifact-free epochs of 5 
seconds (848 samples) were selected. 
MEG data were acquired from 30 subjects. Cognitive 
status was screened in both groups with the Mini Mental 
State Examination (MMSE). The AD group consisted of 
fifteen patients (5 men and 10 women; age = 72.33 ± 9.04 
years, mean ± standard deviation, SD) fulfilling the criteria 
of probable AD, according to the criteria of the National 
Institute of Neurological and Communicative Disorders and 
Stroke - Alzheimer’s and Related Disorders Association. The 
mean MMSE score for the patients was 17.67 ± 3.94 points. 
Patients were free of other significant medical, neurological 
and psychiatric diseases than AD. Moreover, any of the 
participants in the study used medication that could be 
expected to influence in the MEG recording. 
The control group consisted of fifteen control subjects 
without past or present neurological disorders (7 men and 8 
women; age = 72.53 ± 5.40 years, MMSE score = 29.00 ± 
0.33 points). All control subjects and all caregivers of the 
patients gave their informed consent for the participation in 
the current study. The local Ethics Committee approved this 
study.  
B. Detrended Fluctuation Analysis (DFA) 
DFA is a measure widely used for the detection of long-
range correlations and fluctuations in time series [16]. This 
method provides a simple quantitative parameter (the scaling 
exponent) to represent the correlation properties of a signal 
[17]. DFA permits the detection of long-range correlations 
embedded in seemingly non-stationary time series. 
Additionally, it avoids the spurious detection of apparent 
long-range correlations that are an artifact of non-stationarity 
[17]. Given a one dimensional time series X = x1, x2,..., xN, 
we describe the algorithm to compute the DFA [16, 18]: 
1) Integrate the signal X: 
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where X  represents the mean value of X. 
2) The integrated time series Y is divided into windows of 
equal size k. The size of the windows is ranged between 
3 and 84, as one-tenth of the signal length can be 
considered as the maximum window size when using 
DFA [17]. 
3) Within each window, labeled b (b = 1, 2,..., B), perform 
a least-square fit of Y by a straight line bY . This is the 
semilocal trend for the bth window. 
4) Define )(2 kFb  to be the variance of the fluctuation Y 
from bY  in the bth window: 
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5) The square root of the average of )(2 kFb  over all 
windows is the rms fluctuation from the semilocal trends 
in B windows, each having k time points: 
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6) Finally, the study of the dependence of F(k) on the 
window size k is the essence of DFA. If it is a power-law 
behavior F(k) ∝ kα, the scaling exponent is an indicator 
of the nature of the fluctuations in the MEG signals. 
C. Backward Detrended Moving Average (BDMA) 
The detrended moving average (DMA) method is a new 
approach to quantify correlation properties in non-stationary 
signals with underlying trends [19]. Serletis and Rosenberg 
[20] suggested that DMA is an improvement over DFA. 
DMA does not require dividing the series into non-
overlapping windows. Instead, the DMA method detrends the 
series by subtracting a continuous function, the moving 
average. Additionally, DMA is more accurate since the 
moving average is a better low-pass filter when compared to 
the polynomial filter used for DFA [20]. In this study, we 
have used the category of DMA called BDMA [21]. To 
perform the BDMA of a time series X = x1, x2,..., xN,, we 
pursue the following steps [21]: 
1) The signal X is integrated: 
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where X  represents the mean value of X. 
2) The second step of the BDMA is to detect trends in data 
employing a moving average. For a window of size k, 
the backward moving average is defined as: 
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3) Afterwards, the signal is detrended by substracting the 
trend ky~  from the integrated profile Y: 
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4) Then calculate the fluctuation for a window of size k as: 
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5) As in DFA method, a power law relation between the 
fluctuation function F(k) and the scale k indicates a self-
similar behavior. 
  
III. RESULTS 
DFA method was applied for the 148 MEG channels using 
window sizes between 3 and 84 samples. To simplify the 
analyses, the results were averaged over all channels. F(k) as 
a function of k was plotted in a log-log scale, as Fig. 1 
illustrates. If the plot displays a linear scaling region with a 
certain scaling exponent, then there is a power-law behavior 
in the time series [22]. Our results showed two scaling 
regions with different slopes: α1 for 3 ≤ k ≤ 7, and α2 for 14 ≤ 
k ≤ 73. No significant differences were found between the α1 
values of AD patients and control subjects (p = 0.7107 > 
0.01; Student’s t-test). On the other hand, the differences 
between both groups were statistically significant when the 
slopes of the second scaling region were analyzed (p = 
0.0015 < 0.01; Student’s t-test). 
We next apply the BDMA method to the MEG recordings 
with windows sizes between 2 and 84 samples. BDMA 
profiles were obtained representing the natural logarithm of 
F(k) versus the natural logarithm of k (see Fig. 2). This 
scaling analysis method also showed two scaling regions, α1 
and α2. Significant differences between both groups were 
found with α1 (p = 0.0001), whereas the p-value obtained 
with α2 was 0.1065. 
Finally, receiver operating characteristic (ROC) curves 
were used to assess the ability of these measures to 
discriminate AD patients from controls. This method 
summarizes the performance of a two-class classifier across 
the range of possible thresholds. Fig. 3 and 4 represent the 
ROC curves obtained at both scaling regions with DFA and 
BDMA, respectively. The highest accuracy was achieved 
when the slope α2 of DFA was analyzed: 83.33%. In the first 
scale region of BDMA, we achieved the highest value of area 
under the ROC curve (AROC): 0.8667. Table I shows the 
sensitivity, specificity, accuracy and AROC values obtained 
with DFA and BDMA in each scaling region. 
IV. DISCUSSION AND CONCLUSION 
We analyzed the MEG background activity from 15 
patients with probable AD and 15 age-matched control 
subjects by means of DFA and BDMA methods. Our purpose 
was to check the hypothesis that MEG background activity 
was different in AD patients than in control subjects. Both 
measures have proven to be effective in discriminating AD 
patients from controls. Our results revealed that α2 values of 
DFA were significantly lower for the controls than for the 
AD patients. On the other hand, significant differences 
between both groups appear in the first scaling region of 
BDMA. Because both groups were carefully matched for age, 
these changes in the fluctuations of MEG signals may well 
represent the cognitive dysfunction in AD. Additionally, 
accuracies of 83.33% and 80% were reached with DFA and 
BDMA by means of ROC curves.  
Other non-linear methods have been already used to study 
the MEG activity in AD. In [9-11], Lempel-Ziv complexity 
values were significantly lower in the recordings from AD 
patients than in those obtained from control subjects. This 
complexity loss in AD was confirmed using the algorithm of 
fractal dimension proposed by Higuchi [12]. Nevertheless, 
van Cappellen van Walsum et al. [7] suggested that this 
decreased complexity in the MEG background activity of 
AD patients may appear only in the low frequency bands. 
Other MEG studies revealed that brains affected by AD 
show a more regular physiological behaviour [10, 11]. Stam 
et al. [13] found changes of long and short distances 
 
Fig. 1.  DFA profiles, F(k) versus k in a log-log scale, for AD patients 
and control groups. 
 
 
 
 
Fig. 2.  BDMA profiles, F(k) versus k in a log-log scale, for AD 
patients and control groups. 
 
TABLE I 
SENSITIVITY, SPECIFICITY, ACCURACY AND AROC VALUES OBTAINED 
WITH DFA AND BDMA 
 
 
Sensitivity Specificity Acurracy AROC 
α1 of DFA 60.00% 66.67% 63.33% 0.5511 
α2 of DFA 86.67% 80.00% 83.33% 0.8400 
α1 of BDMA 80.00% 80.00% 80.00% 0.8667 
α2 of BDMA 60.00% 86.67% 73.33% 0.6711 
 
 
  
interaction in the frequency bands theta, alpha1, beta and 
gamma using the synchronization likelihood. Finally, AD 
patients have shown a decrease in the mean values of phase 
lag index in the lower alpha and beta bands [14].  
Some limitations of our study merit consideration. Firstly, 
the sample size is small. Thus, a larger database is needed to 
confirm our results. Secondly, our results do not show if 
these measures can detect a gradation of the disease process. 
Therefore, future efforts will be addressed to characterize 
MEG background activity in AD and in other pathologies. It 
is particularly interesting to study MEGs from patients with 
mild cognitive impairment, since several authors have 
considered this disease as a prodromal phase of AD. 
To sum up, our results suggest that both DFA and BDMA 
are appropriate methods to differentiate AD patients from 
elderly controls. Nevertheless, this is a preliminary study and 
a larger database is needed to confirm our results. 
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Fig. 3.  ROC curves showing the discrimination between AD patients 
and control subjects with DFA. 
 
 
Fig. 4.  ROC curves showing the discrimination between AD patients 
and control subjects with BDMA. 
 
